In a mouse model of PDAC, administering the CXCR4 inhibitor AMD3100 (plerixafor) led to the accumulation of T cells among cancer cells, resulting in a synergistic tumoricidal effect when combined with anti-PD-L1 immunotherapy [35]. This evidence concerns the gene CXCR4 and cancer.